메뉴 건너뛰기




Volumn 125, Issue 10, 2012, Pages 981-990

Angiotensin II receptor blocker-based therapy in japanese elderly, high-risk, hypertensive patients

Author keywords

Cardiovascular disease; Clinical trials; Combination therapy; Elderly; High dose angiotensin II receptor blocker; Hypertension; Type 2 diabetes

Indexed keywords

AMLODIPINE; AZELNIDIPINE; OLMESARTAN;

EID: 84866500279     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.12.010     Document Type: Article
Times cited : (49)

References (19)
  • 1
    • 34548383480 scopus 로고    scopus 로고
    • 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension
    • G. Mancia, G. De Backer, A. Dominiczak 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension J Hypertens 25 2007 1751 1762
    • (2007) J Hypertens , vol.25 , pp. 1751-1762
    • Mancia, G.1    De Backer, G.2    Dominiczak, A.3
  • 2
    • 77952304034 scopus 로고    scopus 로고
    • The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
    • T. Ogihara, K. Kikuchi, H. Matsuoka The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) Hypertens Res 32 2009 3 107
    • (2009) Hypertens Res , vol.32 , pp. 3-107
    • Ogihara, T.1    Kikuchi, K.2    Matsuoka, H.3
  • 3
    • 57349138291 scopus 로고    scopus 로고
    • Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
    • K. Jamerson, M.A. Weber, G.L. Bakris Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
    • (2008) N Engl J Med , vol.359 , pp. 2417-2428
    • Jamerson, K.1    Weber, M.A.2    Bakris, G.L.3
  • 4
    • 0035818884 scopus 로고    scopus 로고
    • A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    • J.N. Cohn, G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
    • (2001) N Engl J Med , vol.345 , pp. 1667-1675
    • Cohn, J.N.1    Tognoni, G.2
  • 5
    • 0242490542 scopus 로고    scopus 로고
    • Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    • M.A. Pfeffer, J.J. McMurray, E.J. Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
    • (2003) N Engl J Med , vol.349 , pp. 1893-1906
    • Pfeffer, M.A.1    McMurray, J.J.2    Velazquez, E.J.3
  • 6
    • 0035922444 scopus 로고    scopus 로고
    • The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    • H.H. Parving, H. Lehnert, J. Brochner-Mortensen The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
    • (2001) N Engl J Med , vol.345 , pp. 870-878
    • Parving, H.H.1    Lehnert, H.2    Brochner-Mortensen, J.3
  • 7
    • 0034100147 scopus 로고    scopus 로고
    • Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
    • S. Kim, H. Iwao Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases Pharmacol Rev 52 2000 11 34
    • (2000) Pharmacol Rev , vol.52 , pp. 11-34
    • Kim, S.1    Iwao, H.2
  • 8
    • 52049105198 scopus 로고    scopus 로고
    • Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition
    • E. Yamamoto, Y.F. Dong, K. Kataoka Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition Hypertension 52 2008 573 580
    • (2008) Hypertension , vol.52 , pp. 573-580
    • Yamamoto, E.1    Dong, Y.F.2    Kataoka, K.3
  • 9
    • 67650567354 scopus 로고    scopus 로고
    • Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: A study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients
    • (no. NCT 00134160)
    • H. Ogawa, S. Kim-Mitsuyama, T. Jinnouchi Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials.gov, no. NCT 00134160) Hypertens Res 32 2009 575 580
    • (2009) Hypertens Res , vol.32 , pp. 575-580
    • Ogawa, H.1    Kim-Mitsuyama, S.2    Jinnouchi, T.3
  • 10
    • 33748918856 scopus 로고    scopus 로고
    • Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)
    • Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004) Hypertens Res 29 Suppl 2006 S1 S105
    • (2006) Hypertens Res , vol.29 , Issue.SUPPL.
  • 11
    • 1642464732 scopus 로고    scopus 로고
    • Azelnidipine and amlodipine: A comparison of their pharmacokinetics and effects on ambulatory blood pressure
    • K. Kuramoto, S. Ichikawa, A. Hirai Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure Hypertens Res 26 2003 201 208
    • (2003) Hypertens Res , vol.26 , pp. 201-208
    • Kuramoto, K.1    Ichikawa, S.2    Hirai, A.3
  • 12
    • 36348939350 scopus 로고    scopus 로고
    • Statistics in medicine-reporting of subgroup analyses in clinical trials
    • R. Wang, S.W. Lagakos, J.H. Ware Statistics in medicine-reporting of subgroup analyses in clinical trials N Engl J Med 357 2007 2189 2194
    • (2007) N Engl J Med , vol.357 , pp. 2189-2194
    • Wang, R.1    Lagakos, S.W.2    Ware, J.H.3
  • 13
    • 43549100189 scopus 로고    scopus 로고
    • The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study
    • S.G. Chrysant, M. Melino, S. Karki The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study Clin Ther 30 2008 587 604
    • (2008) Clin Ther , vol.30 , pp. 587-604
    • Chrysant, S.G.1    Melino, M.2    Karki, S.3
  • 14
    • 73849138948 scopus 로고    scopus 로고
    • A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: The REZALT study
    • T. Ogihara, T. Saruta, K. Shimada, K. Kuramoto A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study Hypertens Res 32 2009 1148 1154
    • (2009) Hypertens Res , vol.32 , pp. 1148-1154
    • Ogihara, T.1    Saruta, T.2    Shimada, K.3    Kuramoto, K.4
  • 15
    • 2942635317 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
    • S. Julius, S.E. Kjeldsen, M. Weber Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
    • (2004) Lancet , vol.363 , pp. 2022-2031
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3
  • 16
    • 38549181561 scopus 로고    scopus 로고
    • Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan antihypertensive survival evaluation in Japan trial
    • T. Ogihara, K. Nakao, T. Fukui Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial Hypertension 51 2008 393 398
    • (2008) Hypertension , vol.51 , pp. 393-398
    • Ogihara, T.1    Nakao, K.2    Fukui, T.3
  • 17
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
    • (2002) JAMA , vol.288 , pp. 2981-2997
  • 18
    • 0037108235 scopus 로고    scopus 로고
    • Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems
    • S.J. Pocock, S.E. Assmann, L.E. Enos, L.E. Kasten Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems Stat Med 21 2002 2917 2930
    • (2002) Stat Med , vol.21 , pp. 2917-2930
    • Pocock, S.J.1    Assmann, S.E.2    Enos, L.E.3    Kasten, L.E.4
  • 19
    • 0026911107 scopus 로고
    • Prospective randomized open blinded end-point (PROBE) study A novel design for intervention trials. Prospective Randomized Open Blinded End-Point
    • L. Hansson, T. Hedner, B. Dahlof Prospective randomized open blinded end-point (PROBE) study A novel design for intervention trials. Prospective Randomized Open Blinded End-Point Blood Press 1 1992 113 119
    • (1992) Blood Press , vol.1 , pp. 113-119
    • Hansson, L.1    Hedner, T.2    Dahlof, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.